Protect from direct light and excessive heat
Counterstaining was performed using hematoxylin
Key highlights included @BioNTech BMS (June 2025, $1.5 billion upfront, $2 billion non-contingent, $7.6 billion milestones for PD-L1/VEGF solid tumors), GSK Flagship Pioneering (July 2024, $150 million joint funding, $7.2 billion milestones across 10 immunology/respiratory programs), Pfizer 3SBio (May 2025, $1.3 billion upfront, $100 million equity, $150 million option, $4.8 billion milestones for bispecific immuno-oncology), AstraZeneca CSPC (June 2025, $110 million upfront, $5.2 billion milestones for AI-driven immunology), and Roche Zealand (March 2025, $1.7 billion upfront, $3.6 billion milestones, profit-sharing on obesity drug petrelintide)
The crystal structure of a mammalian fatty acid synthase